Breaking News

ValenzaBio, ProBioGen Enter Cell Line Pact

Aims to maximize cell line productivity leveraging ProBioGen's GlymaxX technology for ValenzaBio's clinical-stage antibody.

By: Kristin Brooks

Managing Editor, Contract Pharma

ProBioGen and ValenzaBio have initiated a cell line development project involving the application of ProBioGen’s GlymaxX technology.
 
ProBioGen will generate a new CHO-based expression system for ValenzaBio’s VB119, a clinical-stage antibody. In addition to the CHO.RiGHT cell line development platform, ProBioGen will apply its ADCC modulating GlymaxX technology. GlymaxX enables a fine tuning of the fucose content of the antibody towards the originator molecule’s fucose content. The GlymaxX technology offers flexibility in terms of fucosylation adjustment and enables its application for innovative molecules as well as for biosimilar projects.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters